Fina Biosolutions LLC is a conjugation CRO/R&D company founded by Andrew Lees. Dr. Lees is the developer of the CDAP conjugation method used by GSK, Pfizer, The Serum Institute of India, and others in their polysaccharide conjugate vaccines. FinaBio has developed FinaXpressTM, an E. coli expression platform for high-titer production of soluble, cytoplasmic disulfide-bonded proteins. The FinaXpressTM platform allows us to produce our GMP-grade CRM197 carrier protein and to offer strain development services for difficult-to-express proteins. The company has built on its conjugation expertise and now manufactures dextran-based reagents, which are used for flow cytometry, bead modification, and a myriad of other applications.